Royalty Pharma PLC (RPRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.74 is considered Undervalued compared with the five-year average of 9.55. The fair price of Royalty Pharma PLC (RPRX) is between 49.71 to 77.42 according to relative valuation method. Compared to the current price of 46.90 USD , Royalty Pharma PLC By Undervalued By 5.64%.

Relative Value

Fair Zone

49.71-77.42

Current Price：46.90

5.64%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Royalty Pharma PLC (RPRX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Royalty Pharma PLC (RPRX) has a current Price-to-Book (P/B) ratio of 2.60. Compared to its 3-year average P/B ratio of 2.15, the current P/B ratio is approximately 20.87% higher. Relative to its 5-year average P/B ratio of 2.53, the current P/B ratio is about 2.61% higher. Royalty Pharma PLC (RPRX) has a Forward Free Cash Flow (FCF) yield of approximately 14.49%. Compared to its 3-year average FCF yield of 19.80%, the current FCF yield is approximately -26.85% lower. Relative to its 5-year average FCF yield of 16.51%, the current FCF yield is about -12.27% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RPRX competitors is 41.75, providing a benchmark for relative valuation. Royalty Pharma PLC Corp (RPRX.O) exhibits a P/S ratio of 4.92, which is -88.21% above the industry average. Given its robust revenue growth of 4.78%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RPRX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RPRX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RPRX currently overvalued or undervalued?

What is Royalty Pharma PLC (RPRX) fair value?

RPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Royalty Pharma PLC (RPRX) is between 49.71 to 77.42 according to relative valuation method.

How does RPRX's valuation metrics compare to the industry average?

The average P/S ratio for RPRX's competitors is 41.75, providing a benchmark for relative valuation. Royalty Pharma PLC Corp (RPRX) exhibits a P/S ratio of 4.92, which is -88.21% above the industry average. Given its robust revenue growth of 4.78%, this premium appears unsustainable.

What is the current P/B ratio for Royalty Pharma PLC (RPRX) as of Mar 02 2026?

As of Mar 02 2026, Royalty Pharma PLC (RPRX) has a P/B ratio of 2.60. This indicates that the market values RPRX at 2.60 times its book value.

What is the current FCF Yield for Royalty Pharma PLC (RPRX) as of Mar 02 2026?

As of Mar 02 2026, Royalty Pharma PLC (RPRX) has a FCF Yield of 14.49%. This means that for every dollar of Royalty Pharma PLC's market capitalization, the company generates 14.49 cents in free cash flow.

What is the current Forward P/E ratio for Royalty Pharma PLC (RPRX) as of Mar 02 2026?

As of Mar 02 2026, Royalty Pharma PLC (RPRX) has a Forward P/E ratio of 7.74. This means the market is willing to pay $7.74 for every dollar of Royalty Pharma PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Royalty Pharma PLC (RPRX) as of Mar 02 2026?

As of Mar 02 2026, Royalty Pharma PLC (RPRX) has a Forward P/S ratio of 4.92. This means the market is valuing RPRX at $4.92 for every dollar of expected revenue over the next 12 months.

RPRX Valuation